Computationally profiling peptide:MHC recognition by T-cell receptors and T-cell receptor-mimetic antibodies

• Published in: Frontiers in immunology Vol. 13; p. 1080596
• Main Authors: Raybould, Matthew I J, Nissley, Daniel A, Kumar, Sandeep, Deane, Charlotte M
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 09.01.2023
• Subjects: Antibodies; antibody; Complementarity Determining Regions - chemistry; Histocompatibility Antigens; HLA; Immunology; Major Histocompatibility Complex; MHC; mimetic; peptide; Peptides; Receptors, Antigen, T-Cell; TCR; TCR-likeness; TCR; peptide; antibody; MHC; mimetic; structural biology; HLA
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.1080596

T-cell receptor-mimetic antibodies (TCRms) targeting disease-associated peptides presented by Major Histocompatibility Complexes (pMHCs) are set to become a major new drug modality. However, we lack a general understanding of how TCRms engage pMHC targets, which is crucial for predicting their specificity and safety. Several new structures of TCRm:pMHC complexes have become available in the past year, providing sufficient initial data for a holistic analysis of TCRms as a class of pMHC binding agents. Here, we profile the complete set of TCRm:pMHC complexes against representative TCR:pMHC complexes to quantify the TCR-likeness of their pMHC engagement. We find that intrinsic molecular differences between antibodies and TCRs lead to fundamentally different roles for their heavy/light chains and Complementarity-Determining Region loops during antigen recognition. The idiotypic properties of antibodies may increase the likelihood of TCRms engaging pMHCs with less peptide selectivity than TCRs. However, the pMHC recognition features of some TCRms, including the two TCRms currently in clinical trials, can be remarkably TCR-like. The insights gained from this study will aid in the rational design and optimisation of next-generation TCRms.